TABLE 1
Basal and clamp characteristics of DIO rats receiving continuous intracerebroventricular infusion of either hFGF21 or vehicle
| Vehicle | hFGF21 | |
|---|---|---|
| n | 6 | 7 |
| Basal | ||
| Body weight (g) | 527.1 ± 18.9 | 561.1 ± 26.7 |
| Δ Body weight (g) | −23.0 ± 3.2 | −25.6 ± 4.4 |
| HFD intake (g/5 days) | 62.6 ± 4.2 | 84.6 ± 4.8* |
| Plasma hFGF21 | N.D. | N.D. |
| Arterial plasma glucose (mg/dl) | 112.2 ± 4.0 | 104.0 ± 5.0 |
| Plasma insulin (ng/ml) | 2.40 ± 0.68 | 2.12 ± 0.54 |
| Plasma nonesterified fatty acids (mmol/l) | 0.39 ± 0.020 | 0.41 ± 0.014 |
| Plasma triglycerides (mg/dl) | 41.0 ± 4.3 | 48.3 ± 6.0 |
| Clamp | ||
| Arterial plasma glucose (mg/dl) | 110.7 ± 5.4 | 116.0 ± 2.4 |
| Plasma insulin (ng/ml) | 6.6 ± 0.35 | 7.1 ± 0.90 |
| GIR (mg/kg/min) | 2.6 ± 0.24 | 4.4 ± 0.10* |
| Hepatic glycogen (ng/mg tissue) | 144.1 ± 12.4 | 152.7 ± 12.5 |
-
Data are means ± SEM. N.D., not determined.
-
*P < 0.05 vs. vehicle.
